Tasigna is the only TKI drug with an actual FDA warning about QT interval prolongation. The Sprycel information is based mainly on lab data plus some minor QT prolongation which has been observed. The FDA des not require a warning on Sprycel, but the manufacturer has suggested monitoring anyway. Gleevec likely has the same issues. As we have discussed, the Tasigna warning seems to have been due somewhat to bad luck during clinical trials, since Sprycel (and probably Gleevec) are similar in actual experience with QT interval. If someone starts out with a long QT interval, this is important issue, otherwise it has not been much of a problem.
Here is some Sprycel specific info on this subject:
http://www.ncbi.nlm....pubmed/20108303
QT Prolongation:
-- In vitro data suggest that SPRYCEL® (dasatinib) has the potential to
prolong cardiac ventricular repolarization (QT interval)
-- In 865 patients with leukemia treated with SPRYCEL in five phase 2
single-arm studies, the maximum mean changes in QTcF (90% upper bound
CI) from baseline ranged from 7.0 ms to 13.4 ms
-- In clinical trials of patients treated with SPRYCEL (n=2440), 15
patients (<1%) had QTc prolongation as an adverse reaction. Twenty-two
patients (1%) experienced a QTcF >500 ms
-- Administer SPRYCEL with caution to patients who have or may develop
prolongation of QTc, including patients with hypokalemia, hypomagnesemia
or congenital long QT syndrome and patients taking anti-arrhythmic drugs
other medicinal products that lead to QT prolongation, and cumulative
high-dose anthracycline therapy
-- Correct hypokalemia or hypomagnesemia prior to SPRYCEL
administration